- Home
- ZYME vs JFR Comparison
ZYME vs JFR Comparison
Compare ZYME & JFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- JFR
- Stock Information
- Founded
- ZYME 2003
- JFR 2004
- Country
- ZYME United States
- JFR United States
- Employees
- ZYME N/A
- JFR N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- JFR Trusts Except Educational Religious and Charitable
- Sector
- ZYME Health Care
- JFR Finance
- Exchange
- ZYME Nasdaq
- JFR Nasdaq
- Market Cap
- ZYME 1.2B
- JFR 1.1B
- IPO Year
- ZYME 2017
- JFR N/A
- Fundamental
- Price
- ZYME $16.56
- JFR $8.08
- Analyst Decision
- ZYME Buy
- JFR
- Analyst Count
- ZYME 7
- JFR 0
- Target Price
- ZYME $20.00
- JFR N/A
- AVG Volume (30 Days)
- ZYME 648.0K
- JFR 621.7K
- Earning Date
- ZYME 10-30-2025
- JFR 01-01-0001
- Dividend Yield
- ZYME N/A
- JFR 11.31%
- EPS Growth
- ZYME N/A
- JFR N/A
- EPS
- ZYME N/A
- JFR N/A
- Revenue
- ZYME $122,867,000.00
- JFR N/A
- Revenue This Year
- ZYME $107.76
- JFR N/A
- Revenue Next Year
- ZYME $2.35
- JFR N/A
- P/E Ratio
- ZYME N/A
- JFR N/A
- Revenue Growth
- ZYME 95.94
- JFR N/A
- 52 Week Low
- ZYME $9.03
- JFR $7.61
- 52 Week High
- ZYME $17.70
- JFR $8.82
- Technical
- Relative Strength Index (RSI)
- ZYME 57.31
- JFR 29.51
- Support Level
- ZYME $16.75
- JFR $8.03
- Resistance Level
- ZYME $17.40
- JFR $8.19
- Average True Range (ATR)
- ZYME 0.58
- JFR 0.07
- MACD
- ZYME -0.06
- JFR -0.01
- Stochastic Oscillator
- ZYME 38.20
- JFR 20.00
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About JFR Nuveen Floating Rate Income Fund
Nuveen Floating Rate Income Fund is a diversified closed-end management investment company. Its investment objective is to achieve a high level of current income, consistent with the preservation of capital. It invests in adjustable-rate U.S. dollar-denominated secured Senior Loans.